Association between exposure to bevacizumab (BV) beyond first progression (BBP) and overall survival (OS) in patients (pts) with metastatic colorectal cancer (mCRC): Results from a large observational study (BRiTE)

Axel Grothey(Campbell Clinic), M. Kozloff(Ingalls Memorial Hospital), Eric Hedrick(Florida Hospital Cancer Institute), D. Purdie(Ingalls Memorial Hospital), Mary M. Sugrue(Ingalls Memorial Hospital), Yi Jiang(Ingalls Memorial Hospital), Wei Dong(Abbott Northwestern Hospital)
Journal of Clinical Oncology
June 20, 2007
10.1200/jco.2007.25.18_suppl.4036
Cited by 55

Related Papers

Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
Encorafenib, Binimetinib, and Cetuximab in <i>BRAF</i> V600E–Mutated Colorectal Cancer
|New England Journal of Medicine|2019|1.5k
Duration of Adjuvant Chemotherapy for Stage III Colon Cancer
|New England Journal of Medicine|2018|1.1k
Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies
|Journal of Clinical Oncology|2012|1.1k
Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study
|The Lancet Oncology|2015|954